
Sudeep Pharma (SUDEEPPHRM) Share Price falls 5.3% to Rs 1,105; market cap at Rs 13,080.58 Cr
Updated: 8 Oct 2026 • 11:25 am
Posted by:

Sudeep Pharma Share Price moved lower in the latest trade, with the stock at Rs 1,105, down 5.3% from the previous close of Rs 1,166.85. The company’s market capitalisation stood at Rs 13,080.58 Cr, placing it in the Mid Cap category. According to latest Univest data, the move keeps Sudeep Pharma Share Price in focus because the decline came after an intraday range that already showed pressure on the day’s low. For investors tracking Sudeep Pharma Share Price Today, the key numbers are the exact price drop, the day range and the valuation profile. The price move is confirmed in Univest data; a company-specific reason has not been established. That makes Sudeep Pharma Stock News relevant mainly as a data-led price event, with fundamentals and sector context providing the next layer of interpretation.
As of 08 October 2026 at 11:23:13 AM IST, Sudeep Pharma Share Price was trading near the day’s low, which helps frame the day’s decline in a factual way. Univest analysis keeps the focus on the visible numbers rather than speculation, so the discussion below moves from price action to fundamental analysis, then to sector comparison and peers. For readers following Sudeep Pharma Share Price Live, the important takeaway is simple: today’s move is measurable, the company is Mid Cap, and the valuation remains well above the healthcare industry benchmark.
Sudeep Pharma (SUDEEPPHRM) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,105 |
| Previous Close | Rs 1,166.85 |
| Today's Move | -Rs 61.85 (-5.3%) |
| Open | Rs 1,190.2 |
| High | Rs 1,190.3 |
| Low | Rs 1,105 |
| Market Capitalisation | Rs 13,080.58 crore |
| Market Cap Category | Mid Cap |
Sudeep Pharma Share Price Today showed a clear decline from the opening print and remained weak through the traded range. The stock opened at Rs 1,190.2, touched a high of Rs 1,190.3 and a low of Rs 1,105, before last trading at Rs 1,105. That places the stock exactly at the day’s low, which is the cleanest way to read the move without adding assumptions. The gap between the previous close of Rs 1,166.85 and the last traded price reflects a fall of Rs 61.85, or 5.3% for the day. The market capitalisation of Rs 13,080.58 Cr keeps Sudeep Pharma Share Price in the Mid Cap bracket. In Sudeep Pharma Share Price news, the price action itself is the event, while Univest data shows no further company-specific trigger. The next step is to see whether Sudeep Pharma Fundamental Analysis supports the same caution or offers a different lens.
Sudeep Pharma (SUDEEPPHRM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 13,080.58 crore |
| P/E Ratio | 72.16x |
| P/B Ratio | 14.26x |
| ROE | 25.37% |
| ROCE | 28.5% |
| EPS | Rs 16.17 |
| Book Value Per Share | Rs 81.8 |
| Dividend Yield | 0.13% |
Sudeep Pharma (SUDEEPPHRM) fundamental metrics show P/E 72.16x, P/B 14.26x, ROE 25.37%, ROCE 28.5%. These ratios show where the company stands today and are not a call to buy or sell.
Sudeep Pharma has a market capitalisation of Rs 13,080.58 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 72.16x, P/B at 14.26x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 25.37% and ROCE of 28.5%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 16.17, book value per share of Rs 81.8, dividend yield of 0.13%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.87x, median ROE of 11.61%, median ROCE of 13.46%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 72.16x |
| Benchmark Median P/E | 31.87x |
| Benchmark Average P/E | 48.48x |
| Benchmark P/E Range | 3.58x to 708.87x |
| Company P/B Ratio | 14.26x |
| Benchmark Median P/B | 2.98x |
| Benchmark Average P/B | 4.31x |
| Company ROE | 25.37% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 28.5% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 13,080.58 crore |
| Benchmark Median Market Cap | Rs 854.81 crore |
| Benchmark Average Market Cap | Rs 14,121.7 crore |
Sudeep Pharma (SUDEEPPHRM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Sudeep Pharma (SUDEEPPHRM) has a P/E ratio of 72.16x, which is above the benchmark median of 31.87x, a difference of +126.42%. A P/E difference of this kind is a reference point rather than a recommendation.
Sudeep Pharma (SUDEEPPHRM) has a ROE of 25.37%, which is above the benchmark median of 11.61%, a difference of +118.52%. Sudeep Pharma (SUDEEPPHRM) has a ROCE of 28.5%, which is above the benchmark median of 13.46%, a difference of +111.74%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,32,120.23 | 35.37 | 4.95 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,53,389.76 | 86.95 | 14.4 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,81,739.76 | 82.14 | 19.96 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,710.44 | 25.51 | 4.27 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,10,980.13 | 101.55 | 19.69 | 18.31 | 18.2 |
Sudeep Pharma (SUDEEPPHRM) has a P/E ratio of 72.16x compared with the displayed peer median of 82.14x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 25.37% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 28.5% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Sudeep Pharma (SUDEEPPHRM) has a market capitalisation of Rs 13,080.58 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Sudeep Pharma
- Sudeep Pharma Share Price fell 5.3% in the latest session, with the stock trading at Rs 1,105.
- The day’s low matched the last traded price, which makes the price action easy to read in exact terms.
- Sudeep Pharma Fundamental Analysis shows ROE of 25.37% and ROCE of 28.5%, both strong on a sector basis.
- The stock trades at a P/E of 72.16 and P/B of 14.26, both above the healthcare industry benchmark.
- Sudeep Pharma Market Cap of Rs 13,080.58 Cr places it in the Mid Cap category and above the industry median market capitalisation.
About Sudeep Pharma
Sudeep Pharma operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company is read here through its market position, pricing profile and return ratios rather than any unsupported operating detail. On the visible numbers, Sudeep Pharma Share Price is supported by strong ROE and ROCE, while the valuation profile remains premium against the industry benchmark. That combination keeps Sudeep Pharma Stock News relevant for investors who follow earnings quality, market capitalisation and relative valuation in the pharma space. The company’s Mid Cap status also matters for context because it places the stock between smaller specialty names and the industry’s largest listed companies.
Track Sudeep Pharma Share Price on Univest
Use Sudeep Pharma (SUDEEPPHRM) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Sudeep Pharma Share Price on Univest for live price movement, fundamental ratios, 52-week levels and market insights in one place. Univest keeps Sudeep Pharma Stock News and Sudeep Pharma Share Price Today in a format that helps readers move from the day’s price fall to valuation and sector comparison. For investors following Sudeep Pharma Share Price Live, the platform also helps compare the stock with healthcare peers and benchmark ratios.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Sudeep Pharma Share Price falling today?
Ans. Sudeep Pharma Share Price fell 5.3% to Rs 1,105 from the previous close of Rs 1,166.85. According to Univest data, the price event is confirmed, but no company-specific catalyst is established, so the move should be read as a data-led.
What is Sudeep Pharma Share Price Today?
Ans. Sudeep Pharma Share Price Today was Rs 1,105. The stock opened at Rs 1,190.2, touched a high of Rs 1,190.3 and a low of Rs 1,105, so the last traded price matched the day’s low during the observed trade.
What does Sudeep Pharma Stock News show?
Ans. Sudeep Pharma Stock News shows a one-day fall of 5.3% alongside a premium valuation profile. The market cap stood at Rs 13,080.58 Cr, while the stock’s P/E and P/B remained well above the same-industry benchmark.
How is Sudeep Pharma valued versus peers?
Ans. Sudeep Pharma trades at a P/E of 72.16 and a P/B of 14.26. That is above Cipla and Sun Pharma on P/E, below Divi’s and Laurus Labs, and above most peers on P/B in the same industry set.
What do ROE and ROCE say about Sudeep Pharma Share Price?
Ans. ROE is 25.37% and ROCE is 28.5%, both stronger than the benchmark median and average for the same industry. Those figures show return quality in the context of a price that still trades at a premium multiple.
What is Sudeep Pharma’s market capitalisation?
Ans. Sudeep Pharma’s market capitalisation is Rs 13,080.58 Cr. That places it in the Mid Cap category and above the industry median market capitalisation of Rs 854.81 Cr, while staying slightly below the industry average.
What is Sudeep Pharma Fundamental Analysis telling investors?
Ans. Sudeep Pharma Fundamental Analysis points to strong return ratios, with EPS at Rs 16.17, book value at Rs 81.8 and dividend yield at 0.13%. The stock also carries a high P/E and P/B versus the healthcare benchmark.
How does Sudeep Pharma compare with the healthcare sector?
Ans. In the same industry benchmark, Sudeep Pharma’s P/E, P/B, ROE and ROCE are all above the median and average. That keeps the stock positioned as a premium name within Healthcare and Pharmaceuticals & Drugs.
Should investors track Sudeep Pharma Share Price on Univest?
Ans. Yes, investors tracking Sudeep Pharma Share Price on Univest can follow live price movement, valuation ratios, peer comparison and 52-week levels together. That makes it easier to read the day’s fall in context rather than in isolation.
Recent Articles

Private Capex Losing Steam in India: Can It Delay the Stock Market Revival? Experts Decode
15 October 2026

BlackRock, ADIA, Norges Seek Anchor Slots in Jio's $3.2 Bn IPO
15 October 2026

ICICI Life Shares Fall 34% in 2026, but Religare Sees 42% Upside | Why?
15 October 2026

Newly Listed Stock Has 30% Upside Potential! JM Financial Issues Buy Call on Shiprocket
15 October 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Private Capex Losing Steam in India: Can It Delay the Stock Market Revival? Experts Decode
BlackRock, ADIA, Norges Seek Anchor Slots in Jio's $3.2 Bn IPO
ICICI Life Shares Fall 34% in 2026, but Religare Sees 42% Upside | Why?
Newly Listed Stock Has 30% Upside Potential! JM Financial Issues Buy Call on Shiprocket
Wipro Q2 Results: Net Profit Falls 2% YoY to Rs 3,200 Crore; Revenue Rises 9%
Popular this week
ICICI Bank, HDFC Bank, SBI, Axis Bank: Which Banking Stock to Buy Ahead of Q2 Results - What Experts Suggest

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





